DK3215530T3 - Forbedrede il-6 antistoffer - Google Patents
Forbedrede il-6 antistoffer Download PDFInfo
- Publication number
- DK3215530T3 DK3215530T3 DK15797538T DK15797538T DK3215530T3 DK 3215530 T3 DK3215530 T3 DK 3215530T3 DK 15797538 T DK15797538 T DK 15797538T DK 15797538 T DK15797538 T DK 15797538T DK 3215530 T3 DK3215530 T3 DK 3215530T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- improved
- Prior art date
Links
- 108090001005 Interleukin-6 Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462077105P | 2014-11-07 | 2014-11-07 | |
US201462087448P | 2014-12-04 | 2014-12-04 | |
US201562247705P | 2015-10-28 | 2015-10-28 | |
PCT/US2015/059532 WO2016073890A1 (en) | 2014-11-07 | 2015-11-06 | Improved il-6 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3215530T3 true DK3215530T3 (da) | 2019-11-25 |
Family
ID=54602042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15797538T DK3215530T3 (da) | 2014-11-07 | 2015-11-06 | Forbedrede il-6 antistoffer |
Country Status (32)
Country | Link |
---|---|
US (2) | US11142571B2 (da) |
EP (3) | EP3215530B9 (da) |
JP (1) | JP6594438B2 (da) |
KR (2) | KR20240023450A (da) |
CN (1) | CN107249631B (da) |
AU (1) | AU2015342882B2 (da) |
BR (1) | BR112017008672A2 (da) |
CA (1) | CA2965689C (da) |
CL (1) | CL2017001135A1 (da) |
CO (1) | CO2017005404A2 (da) |
CR (1) | CR20170231A (da) |
DK (1) | DK3215530T3 (da) |
EA (1) | EA035199B1 (da) |
ES (1) | ES2756275T3 (da) |
HK (1) | HK1244008A1 (da) |
HR (1) | HRP20191945T1 (da) |
HU (1) | HUE046181T2 (da) |
IL (1) | IL251858B (da) |
MA (1) | MA51554A (da) |
MX (2) | MX2017005992A (da) |
MY (1) | MY185114A (da) |
PE (1) | PE20171107A1 (da) |
PH (1) | PH12017500809A1 (da) |
PL (1) | PL3215530T3 (da) |
PT (1) | PT3215530T (da) |
RS (1) | RS59805B1 (da) |
SA (1) | SA517381458B1 (da) |
SG (2) | SG11201703574VA (da) |
SI (1) | SI3215530T1 (da) |
UA (1) | UA122673C2 (da) |
WO (1) | WO2016073890A1 (da) |
ZA (1) | ZA201702985B (da) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20181363A1 (es) | 2015-09-23 | 2018-08-27 | Genentech Inc | Variantes optimizadas de anticuerpos anti-vegf |
BR112018017031A2 (pt) * | 2016-02-23 | 2019-01-22 | Sesen Bio Inc | formulações de antagonista de il-6 e usos das mesmas |
US20200347143A1 (en) * | 2016-12-19 | 2020-11-05 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
IL269506B2 (en) | 2017-03-22 | 2024-04-01 | Genentech Inc | Hyaluronic acid cross-linked hydrogel preparations and methods |
KR20190138636A (ko) | 2017-03-22 | 2019-12-13 | 제넨테크, 인크. | 안구 장애의 치료를 위한 최적화된 항체 조성물 |
CN109867723B (zh) * | 2017-12-05 | 2022-06-17 | 南京金斯瑞生物科技有限公司 | 抗人il6单克隆抗体及其制备方法和用途 |
BR112022018254A2 (pt) | 2020-03-13 | 2022-10-25 | Genentech Inc | Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo |
EP4126949A1 (en) | 2020-03-24 | 2023-02-08 | Genentech, Inc. | Tie2-binding agents and methods of use |
EP4228702A1 (en) | 2020-10-15 | 2023-08-23 | F. Hoffmann-La Roche AG | Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery |
CN114525235B (zh) * | 2022-02-25 | 2023-07-14 | 郑州大学 | 一种提高人表皮生长因子分泌生产效率的方法 |
TW202426494A (zh) * | 2022-10-24 | 2024-07-01 | 瑞士商赫孚孟拉羅股份公司 | 預測對il-6拮抗劑的反應 |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
JP4146512B2 (ja) | 1991-03-01 | 2008-09-10 | ダイアックス コープ. | 小型タンパク質 |
PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
FR2734739B1 (fr) | 1995-06-01 | 1997-07-11 | Gec Alsthom Stein Ind | Dispositif de surveillance d'un broyeur a boulets |
TW311927B (da) | 1995-07-11 | 1997-08-01 | Minnesota Mining & Mfg | |
EP0795743A3 (en) | 1996-03-15 | 1998-02-25 | Japan Tobacco Inc. | Method and apparatus for infra-red moisture measurement |
US5839430A (en) | 1996-04-26 | 1998-11-24 | Cama; Joseph | Combination inhaler and peak flow rate meter |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
CA2288600C (en) | 1997-05-02 | 2010-06-01 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
US6358058B1 (en) | 1998-01-30 | 2002-03-19 | 1263152 Ontario Inc. | Aerosol dispensing inhaler training device |
ATE439592T1 (de) | 1998-12-10 | 2009-08-15 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
WO2002088171A2 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
AU2002363339B2 (en) | 2001-11-08 | 2008-02-07 | Abbvie Biotechnology Ltd | Stable liquid pharmaceutical formulation of IGG antibodies |
EP1503731A1 (en) | 2002-05-07 | 2005-02-09 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
CA2506230A1 (en) * | 2002-11-15 | 2004-06-03 | Centocor, Inc. | Anti-angiogenic uses of il-6 antagonists |
EP2402756A3 (en) | 2003-12-23 | 2012-02-22 | Rinat Neuroscience Corp. | Agonist anti-trkC antibodies and methods using same |
JP5055603B2 (ja) | 2004-08-04 | 2012-10-24 | メントリック・バイオテック・リミテッド・ライアビリティ・カンパニー | 変異Fc領域 |
WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
BRPI0620797A2 (pt) | 2005-12-30 | 2011-11-22 | Merck Patent Ges Mit Beschonkter Haftung | anticorpos anti-il-6 que previnem a ligação de il-6 complexado com il-6ralfa a gp130 |
CA2644405A1 (en) | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
US20070269868A1 (en) | 2006-05-19 | 2007-11-22 | Carvalho Jensen Anne E | Culture method for obtaining a clonal population of antigen-specific B cells |
BRPI0811782A2 (pt) * | 2007-05-21 | 2019-02-26 | Alder Biopharmaceuticals, Inc. | anticorpos para il-6 e uso dos mesmos |
PT2198007T (pt) | 2007-09-14 | 2018-01-29 | Sanofi Pasteur Biologics Llc | Composições farmacêuticas contendo toxoides a e b de clostridium difficile |
CN101925611A (zh) | 2007-11-21 | 2010-12-22 | 安姆根有限公司 | Wise结合剂和表位 |
US20100187601A1 (en) | 2007-12-12 | 2010-07-29 | Fujio Masuoka | Semiconductor device |
BRPI0907186A2 (pt) | 2008-01-15 | 2015-07-14 | Abbott Gmbh & Co Kg | Composições proteicas pulverizadas e métodos para sua produção |
AR072897A1 (es) | 2008-08-05 | 2010-09-29 | Novartis Ag | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 |
JP5033921B2 (ja) | 2008-09-12 | 2012-09-26 | 株式会社ケーディエフ | 噴水装置 |
WO2010039750A2 (en) | 2008-10-01 | 2010-04-08 | Monsanto Technology Llc | Transgenic plants with enhanced agronomic traits |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
MX2011005540A (es) | 2008-11-26 | 2011-06-21 | Glaxo Group Ltd | Polipeptidos dominios variables de anticuerpos, y antagonistas. |
AU2010208125B2 (en) | 2009-01-29 | 2015-02-12 | Medimmune, Llc | Human anti-IL-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
SG186451A1 (en) | 2010-07-12 | 2013-01-30 | Covx Technologies Ireland Ltd | Multifunctional antibody conjugates |
JP6154900B2 (ja) | 2012-07-13 | 2017-06-28 | ロシュ グリクアート アクチェンゲゼルシャフト | 二重特異性抗vegf/抗ang−2抗体及び眼血管疾患の処置におけるそれらの使用 |
SG11201502659YA (en) | 2012-10-25 | 2015-05-28 | Medimmune Llc | Stable, low viscosity antibody formulation |
CN104903349B (zh) * | 2012-11-08 | 2018-10-19 | 十一生物治疗股份有限公司 | Il-6拮抗剂及其应用 |
EP3628373A1 (en) | 2013-07-12 | 2020-04-01 | IVERIC bio, Inc. | Methods for treating or preventing opthalmological conditions |
WO2016073894A1 (en) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
-
2015
- 2015-11-06 MX MX2017005992A patent/MX2017005992A/es unknown
- 2015-11-06 CA CA2965689A patent/CA2965689C/en active Active
- 2015-11-06 KR KR1020247004699A patent/KR20240023450A/ko not_active Application Discontinuation
- 2015-11-06 AU AU2015342882A patent/AU2015342882B2/en active Active
- 2015-11-06 JP JP2017543332A patent/JP6594438B2/ja active Active
- 2015-11-06 CN CN201580065652.6A patent/CN107249631B/zh active Active
- 2015-11-06 SG SG11201703574VA patent/SG11201703574VA/en unknown
- 2015-11-06 RS RS20191447A patent/RS59805B1/sr unknown
- 2015-11-06 US US15/524,727 patent/US11142571B2/en active Active
- 2015-11-06 SI SI201530995T patent/SI3215530T1/sl unknown
- 2015-11-06 EP EP15797538.4A patent/EP3215530B9/en active Active
- 2015-11-06 UA UAA201705592A patent/UA122673C2/uk unknown
- 2015-11-06 ES ES15797538T patent/ES2756275T3/es active Active
- 2015-11-06 CR CR20170231A patent/CR20170231A/es unknown
- 2015-11-06 EA EA201791005A patent/EA035199B1/ru not_active IP Right Cessation
- 2015-11-06 PE PE2017000804A patent/PE20171107A1/es unknown
- 2015-11-06 SG SG10202103420PA patent/SG10202103420PA/en unknown
- 2015-11-06 EP EP19189890.7A patent/EP3632931A1/en active Pending
- 2015-11-06 BR BR112017008672-7A patent/BR112017008672A2/pt active Search and Examination
- 2015-11-06 DK DK15797538T patent/DK3215530T3/da active
- 2015-11-06 PL PL15797538T patent/PL3215530T3/pl unknown
- 2015-11-06 MY MYPI2017000609A patent/MY185114A/en unknown
- 2015-11-06 WO PCT/US2015/059532 patent/WO2016073890A1/en active Application Filing
- 2015-11-06 KR KR1020177014412A patent/KR102636726B1/ko active IP Right Grant
- 2015-11-06 PT PT157975384T patent/PT3215530T/pt unknown
- 2015-11-06 IL IL251858A patent/IL251858B/en unknown
- 2015-11-06 EP EP23189385.0A patent/EP4268843A3/en active Pending
- 2015-11-06 MA MA051554A patent/MA51554A/fr unknown
- 2015-11-06 HU HUE15797538A patent/HUE046181T2/hu unknown
-
2017
- 2017-04-28 ZA ZA201702985A patent/ZA201702985B/en unknown
- 2017-05-02 PH PH12017500809A patent/PH12017500809A1/en unknown
- 2017-05-03 SA SA517381458A patent/SA517381458B1/ar unknown
- 2017-05-05 CL CL2017001135A patent/CL2017001135A1/es unknown
- 2017-05-08 MX MX2021008663A patent/MX2021008663A/es unknown
- 2017-05-30 CO CONC2017/0005404A patent/CO2017005404A2/es unknown
-
2018
- 2018-03-10 HK HK18103370.4A patent/HK1244008A1/zh unknown
-
2019
- 2019-10-25 HR HRP20191945TT patent/HRP20191945T1/hr unknown
-
2021
- 2021-09-13 US US17/473,696 patent/US20220169719A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL301117I1 (nl) | trastuzumab deruxtecan | |
DK3344654T3 (da) | Anti-lag-3-antistoffer | |
KR102355950B9 (ko) | Tigit에 대한 항체 | |
DK3126395T3 (da) | Multispecifikke antistoffer | |
DK3556777T3 (da) | Multispecifikke antistofkonstrukter | |
DK3183272T3 (da) | Asymmetriske multispecifikke antistoffer | |
BR112017001385A2 (pt) | anticorpos anti-pd-1 | |
DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
KR20180085002A (ko) | 인간화된 항-cll-1 항체 | |
DK3157559T3 (da) | Anti-axl-antistoffer | |
CL2016001742A1 (es) | Anticuerpos anti-baff novedosos | |
HK1244008A1 (zh) | 改進的il-6抗體 | |
DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
DK3099791T3 (da) | Protein | |
DK3484921T3 (da) | Anti-IL-22R antistoffer | |
ITUB20155097A1 (it) | Anticorpi umanizzati anti-BAG3 | |
DK3126391T3 (da) | ANTISTOFFER MOD HPA-1a | |
DK3099793T3 (da) | Protein | |
FI20145330A (fi) | Immunomääritys | |
BR112017002234A2 (pt) | anticorpos anti-pd-l1 | |
UA30337S (uk) | Карбюратор | |
UA30336S (uk) | Карбюратор | |
UA30317S (uk) | Карбюратор | |
UA30329S (uk) | Карбюратор | |
DE112015004618A5 (de) | Garnitur |